Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198361 | 0.94 | EGFR (0.49) | EGFRERBB2MKNK1 | |
| SCHEMBL2194064 | 0.94 | EGFR (0.48) | EGFRERBB2 | |
| SCHEMBL2194859 | 0.93 | EGFR (0.59) | EGFRERBB2 | |
| SCHEMBL2196578 | 0.92 | EGFR (0.48) | EGFRERBB2MKNK1 | |
| SCHEMBL2195355 | 0.91 | EGFR (0.47) | EGFRERBB2 | |
| SCHEMBL2194192 | 0.91 | EGFR (0.48) | EGFRERBB2 | |
| SCHEMBL2194979 | 0.91 | EGFR (0.46) | EGFRERBB2MKNK1 | |
| SCHEMBL2194943 | 0.90 | EGFR (0.50) | EGFRERBB2 | |
| SCHEMBL2193853 | 0.89 | EGFR (0.47) | EGFRERBB2 | |
| SCHEMBL2193775 | 0.89 | EGFR (0.46) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | EGFR 2146/4885ERBB2 1762/4885MKNK1 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.